<DOC>
	<DOCNO>NCT02458638</DOCNO>
	<brief_summary>The primary efficacy objective study evaluate non-progression rate ( NPR ) 18 week participant advance solid tumor treat atezolizumab , define percentage participant complete response ( CR ) , partial response ( PR ) , stable disease ( SD ) assess Investigator accord Response Evaluation Criteria Solid Tumors version 1.1 ( RECIST v1.1 ) , accord disease-specific criterion prostate cancer malignant pleural mesothelioma .</brief_summary>
	<brief_title>An Open-Label Study Atezolizumab Advanced Solid Tumors</brief_title>
	<detailed_description />
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Male female Histologically document advanced solid tumor progress follow least one line prior systemic therapy alternative therapy prolong survival exist proven benefit Representative formalinfixed paraffinembedded ( FFPE ) tumor specimens paraffin block ( prefer ) freshly cut unstained slide ( exceptional case ) associate pathology report central test Measurable disease define RECIST v1.1 diseasespecific criterion prostate cancer malignant pleural mesothelioma Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 Negative serum pregnancy test result within 14 day prior study drug among woman childbearing potential Hematologic malignancy , nonsmall cell lung carcinoma ( NSCLC ) , triplenegative breast cancer , urothelial bladder cancer , renal cell carcinoma , melanoma malignant skin cancer ( except Merkel cell carcinoma ) , hepatocellular carcinoma , cancer unknown primary , glioblastoma Malignancies disease study within 5 year prior Day 1 Cycle 1 except negligible risk metastasis death Uncontrolled tumorrelated pain Uncontrolled pleural effusion , pericardial effusion , ascites require recurrent drainage procedure greather equal ( &gt; /= ) 1 time per month History asymptomatic symptomatic central nervous system ( CNS ) metastasis Leptomeningeal disease Spinal cord compression definitively treat surgery and/or radiation , previously treat without evidence disease clinically stable &gt; /=2 week prior Day 1 Cycle 1 Pregnant lactate woman Significant cardiovascular disease within 3 month prior Day 1 Cycle 1 Severe infection within 4 week prior Day 1 Cycle 1 Oral IV antibiotic within 2 week prior Day 1 Cycle 1 History severe allergic , anaphylactic , hypersensitivity reaction chimeric humanize antibody fusion protein Known hypersensitivity allergy biopharmaceuticals produce Chinese hamster ovary cell component atezolizumab formulation History autoimmune disease except treated/stable hypothyroidism Type 1 diabetes mellitus Active tuberculosis Signs symptom infection within 2 week prior Day 1 Cycle 1 Prior treatment cluster differentiation ( CD ) 137 agonist immune checkpoint blockade therapy , antiprogrammed cell death 1 ( PD1 ) , antiprogrammed cell death ligand 1 ( PDL1 ) therapeutic antibody Treatment systemic corticosteroid systemic immunosuppressive medication within 2 week prior Day 1 Cycle 1 , anticipate requirement systemic immunosuppressive medication trial</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>